Fusion Antibodies Plc (GB:FAB) has released an update.
Fusion Antibodies Plc, a specialist in pre-clinical antibody discovery and engineering, reported strong performance in the first quarter of FY2025 with unaudited revenues of approximately £522k, doubling from the previous year. The company has secured its first OptiPhage contract, is collaborating with the National Cancer Institute, and has a robust sales pipeline with an order book valued at £0.7m expected to be recognized within the financial year. CEO Adrian Kinkaid expresses confidence in the ongoing strategy, which is substantiated by the growing revenue, new orders, and a forward-looking aim for sustainable growth and business success.
For further insights into GB:FAB stock, check out TipRanks’ Stock Analysis page.
